Gene expression of TDO and IDO1 in ovarian cancer cell samples isolated from ascites.
Expression of Cancer Immunotherapy Targets in Patient Material
Oss, March, 04th, 2020 – ESMO has made the decision not to proceed with the TAT 2020 Congress in due consideration of the spread of the Coronavirus infections. NTRC’s poster that would have been presented at the Congress can be accessed via the link below. The poster shows that high surface expression of PD-L1, and high expression of IDO1 or TDO2 was observed in several ovarian cancer-associated cell samples isolated from malignant ascites. In an ongoing study, in which hundred patients with high-grade serous ovarian cancer will be included, NTRC determines the immune status of the ascites, the in vitro drug response of tumor cells isolated from ascites, and the cancer gene mutation status. Results are related to clinical responses.
NTRC is a precision medicine company dedicated to discovering new anti cancer drug candidates. It is our mission to help you finding a mechanistic hypothesis before entering the clinic. We provide cell-based profiling services, target residence time measurements and biochemical profiling. We can study a wide range of cancer cells, primary patient material and immune cells in vitro, in isolation and in coculture, after exposure to monotherapy and combination therapy. Keywords are: Quality. Flexibility. Short Turnaround Time.